Fed. Circ. Backs Decision Clearing Pfizer On Heart Drug IP
The Federal Circuit has shot down Gilead Sciences' and Astellas' argument that they were wrongly barred from responding to amendments Pfizer's Hospira Inc. unit made to an abbreviated new drug application...To view the full article, register now.
Already a subscriber? Click here to view full article